Applied Therapeutics (APLT) Projected to Post Earnings on Thursday

Applied Therapeutics (NASDAQ:APLT) will likely be posting its Q3 2025 results before the market opens on Thursday, November 6th. Analysts expect the company to announce earnings of ($0.15) per share for the quarter. Interested persons are encouraged to explore the company’s upcoming Q3 2025 earningoverview page for the latest details on the call scheduled for Monday, November 10, 2025 at 4:00 PM ET.

Applied Therapeutics (NASDAQ:APLT) last released its quarterly earnings data on Wednesday, August 13th. The company reported ($0.15) earnings per share for the quarter, beating the consensus estimate of ($0.17) by $0.02. On average, analysts expect Applied Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Applied Therapeutics Price Performance

Applied Therapeutics stock opened at $1.22 on Thursday. The company has a market capitalization of $175.69 million, a PE ratio of -2.71 and a beta of 2.07. Applied Therapeutics has a one year low of $0.30 and a one year high of $10.62. The business has a 50 day simple moving average of $0.79 and a 200 day simple moving average of $0.54.

Hedge Funds Weigh In On Applied Therapeutics

A hedge fund recently raised its stake in Applied Therapeutics stock. Marshall Wace LLP lifted its holdings in shares of Applied Therapeutics Inc. (NASDAQ:APLT) by 18.1% during the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 1,544,191 shares of the company’s stock after purchasing an additional 236,810 shares during the period. Marshall Wace LLP owned 1.09% of Applied Therapeutics worth $479,000 at the end of the most recent reporting period. 98.31% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on APLT shares. Wall Street Zen upgraded Applied Therapeutics to a “sell” rating in a research note on Saturday, July 26th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Applied Therapeutics in a report on Tuesday, October 14th. Two equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Applied Therapeutics presently has an average rating of “Hold” and an average price target of $4.13.

Applied Therapeutics Company Profile

Applied Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG.